Vaccines:  There are 10 vaccine candidates in clinical trials for efficacy.  More than 100 candidates in pre-clinical stages.  The three manufacturers that have promising candidates are Moderna, Pfizer/BioNTech and AstraZeneca/University of Oxford (UK).

Remdesivir:  The second shipment of 940,000 vials is scheduled for June and will treat approximately 120,000 patients.  At this time, there is no estimated date of when this drug will be commercially available.  The FDA still considers it an investigational drug at this time.